Claims that it can cure 60% of solid tumors

Doctors were paid from $100,000 to $1.9M.by.drug Companies for review drug applications

Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. The rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group. And yet when you look at the trial results, overall survival was 2 months longer…

In the latest ASCO conference, there’s is a problem of hyping results of a few patient responses.

How FDA insiders describe the culture of approving drugs

How an oncologist tweets at how cancer treatments are a big scam

A database is now being conducted to study the parameters for why certain patients respond exceptionally with chemotherapy

Authors pay “open access peer review” journals to publish an article

How turmeric kills Cancer cells

MDA 9 SYNTHENIN inhibition can stop GBM stem cells from multiplying